NewEdge Wealth LLC Buys New Holdings in Bristol Myers Squibb Company $BMY

NewEdge Wealth LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, HoldingsChannel.com reports. The fund purchased 18,530 shares of the biopharmaceutical company’s stock, valued at approximately $1,068,000.

Several other hedge funds have also modified their holdings of BMY. Vanguard Group Inc. boosted its stake in Bristol Myers Squibb by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the period. BlackRock Inc. grew its holdings in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp increased its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC lifted its holdings in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Norges Bank purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at about $1,947,272,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Roth Capital began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Jefferies Financial Group downgraded Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Finally, Citigroup reaffirmed a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $67.06 on Friday. The company has a 50 day moving average price of $60.55 and a 200-day moving average price of $59.37. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The stock has a market capitalization of $136.98 billion, a PE ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.